000			03606nam a22003855i 4500
999			_c106743 _d106743
001			106743
003			ES-MaUEC
005			20230102113311.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			171124s2018 gw | s |||| 0|eng d
020			_a9783319659213
024	7		_a10.1007/978-3-319-65921-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC377 _b2018 EB
245	0	0	_aProgressive Multiple Sclerosis _cedited by Alastair Wilkins
250			_a2nd ed. 2018.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2018
300			_a1 recurso en línea (IX, 307 páginas) _b21 ilustraciones, 6 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
490	0		_aMedicine (Springer-11650)
505	0		_aGeneral introduction -- What is disease progression?- Clinical scales of disease progression and disability -- Primary progressive MS -- Epidemiology of progressive multiple sclerosis -- The neuropathology of progressive multiple sclerosis -- Mechanisms of disease progression -- Axonal injury -- Imaging disease progression -- Biomarkers of disease progression -- Symptomatic treatment for progressive multiple sclerosis -- Trials of licenced RRMS disease modifying therapies in progressive MS -- Trials of novel therapies specifically for progressive MS -- Rehabilitation -- Future therapies for progressive multiple sclerosis.
520			_aThis revised, updated second edition draws together the basic science, pathology, epidemiology and treatment possibilities in progressive multiple sclerosis. Each chapter addresses specific aspects of progressive multiple sclerosis providing an extensive review of the current literature and a discussion of the likely mechanisms of tissue injury relevant to the disease. New additions to the second edition include a description of clinical scales used to determine levels of disability; recent trials specifically directed at reducing disease progression; rehabilitation; and an in depth discussion of the similarities and differences between primary and secondary multiple sclerosis. The biological processes underlying disease progression are elucidated as are specific pathophysiological mechanisms. The basic science of axonal degeneration and the clinical understanding of progressive multiple sclerosis are discussed in the context of emerging and future therapies for disease progression as are trials which have been and will be conducted for progressive multiple sclerosis. An overview of biomarkers for the disease is included and existing symptomatic therapies for progressive multiple sclerosis are covered in detail. Progressive Multiple Sclerosis, Second Edition is ideal for both general neurologists and those with a specialist interest in multiple sclerosis. It will also be of interest to neurologists in training and other medical professionals treating this common disease.
988			_aSpringer_Medicine_2018
650		7	_2embne _9142007 _aEsclerosis múltiple
700	1		_aWilkins, Alastair. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783319659206
776	0	8	_iPrinted edition: _z9783319659220
776	0	8	_iPrinted edition: _z9783319881324
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-65921-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b02/2019 _dz _feng _ggw _h0